N/A
N=8,790
Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022)
Perennial Allergic Rhinitis · Seasonal Allergic Rhinitis
Bottom Line
View on ClinicalTrials.gov: NCT01549340 ↗Enrolled (actual)
8,790
Serious AEs
—
Results posted
Mar 2014
Primary outcome: Primary: Percentage of Participants Advised to Start AIT Who Elected Subcutaneous Immunotherapy (SCIT) Shots or Sublingual Immunotherapy (SLIT) Drops — 28.2; 8.0 percentage of participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- ALK-Abelló A/S
- Primary completion
- May 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Advised to Start AIT Who Elected Subcutaneous Immunotherapy (SCIT) Shots or Sublingual Immunotherapy (SLIT) Drops |
28.2; 8.0 | — |
| PRIMARY Percentage of Participants Who Initiated SCIT or SLIT and Completed 5 Years of Treatment |
10.8; 2.6 | — |
| PRIMARY Duration of Treatment With SCIT or SLIT |
2.4; 1.9 | — |
| PRIMARY Reason for Discontinuation of SCIT or SLIT More Than 6 Months Before Completion of the Recommended Course |
67; 69; 7; 4; 1; 3 | — |
| SECONDARY Percentage of Participants With a Co-morbidity of Asthma Who Initiated SCIT or SLIT |
25.2; 8.7 | — |
| SECONDARY Duration of SCIT or SLIT Treatment for Participants With AR and Asthma or AR Alone |
2.4; 2.4; 2.1; 1.8 | — |
Summary
The purpose of this study is to determine the proportion of participants that initiate allergen immunotherapy (AIT) upon the recommendation of their physician and the proportion of participants that persist with their AIT throughout the recommended course.
Eligibility Criteria
Inclusion Criteria
- Diagnosis of AR with or without allergic conjunctivitis (AC)
- Documented provider-to-patient or parent discussion of AIT as a treatment option
Exclusion Criteria
- Participants receiving AIT as an AR treatment without documented provider-to-patient or parent discussion of AIT as a treatment option
- Participants receiving immunotherapy for insect sensitivities only
- AIT started before 2005
Data sourced from ClinicalTrials.gov (NCT01549340). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.